Comments
Drug firm Ranbaxy Laboratories today said the DC Federal Court in the U.S. has not granted the company temporary restraining order to block the U.S. health regulator from approving other ANDAs for generic versions of digestive disorder medicine Nexium and anti-viral Valcyte.
“The Court has not granted temporary restraining order to block FDA approval for other Abbreviated New Drug Applications (ANDAs) for generic version of Nexium and Valganciclovir,” Ranbaxy Laboratories said in a filing to the BSE.
However, the court ordered the parties to the suit to agree upon a schedule for filing additional legal briefs, addressing Ranbaxy’s request for a preliminary injunction by November 21, 2014, it added.
Ranbaxy Laboratories had sued USFDA over revoking an approval to sell generic versions of Nexium and Valcyte in the US market.
It had also sought restraining the approval given by the USFDA to Dr Reddy’s Laboratories and Endo Pharmaceuticals from launching generics of Valcyte.
While revoking Ranbaxy’s approval for the two drugs, the USFDA cited adverse compliance status of Ranbaxy’s Paonta and Dewas facilities and it was “accordingly... correcting its mistake and rescinding the tentative approval letters issued regarding these ANDAs.”
As per the lawsuit filed in the U.S. District Court of Columbia, the company had sought “immediate judicial review” of a November 4 decision of the U.S. Food and Drug Administration (USFDA) that stripped Ranbaxy of “its statutory rights” and “literally hundreds of millions of dollars in anticipated revenues for certain generic versions of the brand-name drugs Nexium and Valcyte.”
Ranbaxy, however, in its suit had said the USFDA “has no power to correct an alleged ‘mistake’ it made six years ago.”
“Nothing in the FDCA permits FDA to revoke the issuance of a tentative approval and even if the agency did have such authority, it was not timely exercised here.”
USFDA not only was aware of the relevant facilities’ compliance issues at the time it granted tentative approval (TA) to Ranbaxy’s ANDAs, but senior FDA officials, including those at the highest levels, considered and determined that those products were eligible for TA despite the known compliance issues at relevant facilities, the company said in its petition.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.